Staphylococcus aureus with reduced susceptibility to vancomycin in a dialysis graft.

3. Critchley IA, Blosser-Middleton RS, Jones ME, Thornsberry C, Sahm DF, Karlowsky JA. Baseline study to determine in vitro activities of daptomycin against gram-positive pathogens isolated in the United States in 2000–2001. Antimicrob Agents Chemother 2003; 47: 1689–93. 4. Critchley IA, Draghi DC, Sahm DF, Thornsberry C, Jones ME, Karlowsky JA. Activity of daptomycin against susceptible and multidrug-resistant gram-positive pathogens collected in the SECURE study (Europe) during 2000–2001. J Antimicrob Chemother 2003; 51: 639–49. 5. Snydman DR, Jacobus NV, McDermott LA, Lonks JR, Boyce JM. Comparative in vitro activities of daptomycin and vancomycin against resistant gram-positive pathogens.Antimicrob Agents Chemother 2000; 44:3447–50. 6. Matushek MG, Bonten MJM, Hayden MK. Rapid preparation of bacterial DNA for pulsed-field gel electrophoresis. J Clin Microbiol 1996; 34:2598–600. 7. NCCLS. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically: approved standard M7-A6. 6th ed., Vol. 23. Wayne, PA: NCCLS, 2003. 8. NCCLS. Fourteenth informational supplement: NCCLS document M100-S14. Villanova, PA: NCCLS, 2004. 9. Kauffman CA. Therapeutic and preventative options for the management of vancomycinresistant enterococcal infections. J Antimicrob Chemother 2003; 51S:iii23–30. 10. Silverman JA, Oliver N, Andrew T, Tongchuan L. Resistance studies with daptomycin. Antimicrob Agents Chemother 2001; 45:1799–802.